Variant report
Variant | nsv543254 |
---|---|
Chromosome Location | chr17:19515267-19527596 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:86)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
Variant related genes | Relation type |
---|---|
ENSG00000231625 | TF binding region |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs145486326 | chr17:19515305-19515306 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs28672208 | chr17:19515344-19515345 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
3 | rs551482252 | chr17:19515408-19515409 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs192782111 | chr17:19515415-19515416 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs183829704 | chr17:19515443-19515444 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs188163300 | chr17:19515559-19515560 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs533050266 | chr17:19515593-19515594 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs548007194 | chr17:19515689-19515690 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs11650399 | chr17:19515695-19515696 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
10 | rs111572638 | chr17:19515709-19515710 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs537473615 | chr17:19515740-19515741 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs56822969 | chr17:19515745-19515746 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
13 | rs138114789 | chr17:19515755-19515756 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs142705753 | chr17:19515773-19515774 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs567451470 | chr17:19515867-19515868 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs537370165 | chr17:19515882-19515883 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs557513616 | chr17:19515953-19515954 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs150509195 | chr17:19516016-19516017 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs539541145 | chr17:19516042-19516043 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs553053481 | chr17:19516056-19516057 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs78569838 | chr17:19516085-19516086 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs75492580 | chr17:19516087-19516088 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs572861044 | chr17:19516140-19516141 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs12604069 | chr17:19516216-19516217 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
25 | rs138357626 | chr17:19516239-19516240 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs575480856 | chr17:19516278-19516279 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs544221764 | chr17:19516287-19516288 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs369990383 | chr17:19516391-19516392 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs564303730 | chr17:19516494-19516495 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs149248138 | chr17:19516500-19516501 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs144479439 | chr17:19516566-19516567 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs560308672 | chr17:19516778-19516779 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs34304734 | chr17:19516786-19516787 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs534846189 | chr17:19516864-19516865 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs548944668 | chr17:19516874-19516875 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs572217418 | chr17:19517054-19517055 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs568792110 | chr17:19517065-19517066 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs576296356 | chr17:19517146-19517147 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs531223336 | chr17:19517172-19517173 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs377698526 | chr17:19517173-19517174 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs534568183 | chr17:19517238-19517239 | Bivalent Enhancer Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs558055452 | chr17:19517332-19517333 | Bivalent Enhancer Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
43 | rs570663869 | chr17:19517352-19517353 | Bivalent Enhancer Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
44 | rs539654555 | chr17:19517406-19517407 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
45 | rs553014703 | chr17:19517407-19517408 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
46 | rs566644451 | chr17:19517423-19517424 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
47 | rs139585788 | chr17:19517433-19517434 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
48 | rs555724697 | chr17:19517451-19517452 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
49 | rs575596528 | chr17:19517470-19517471 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
50 | rs553303854 | chr17:19517471-19517472 | Enhancers Bivalent Enhancer Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Burkitt''s lymphoma | 19759907 | CNVD |
Wilms tumour | 21544195 | CNVD |
Esophageal adenocarcinoma | 18519675 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Acute lymphoblastic leukemia | 21390130 | CNVD |
Melanoma | 18172304 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Breast cancer | 16608533 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Chordoma | 21602918 | CNVD |
Miller-Dieker syndrome | 22283845 | CNVD |
Non-syndromic sensorineural hearing loss | 17457615 | CNVD |
Cancer | 22429812 | CNVD |
Chronic lymphocytic leukemia | 21795749 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Follicular lymphoma | 19010834 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Paraganglioma | 21461997 | CNVD |
Pheochromocytoma | 21461997 | CNVD |
Breast cancer | 22028636 | CNVD |
Breast cancer | 20837533 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 21264507 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Medulloblastoma | 21292688 | CNVD |
colon cancer | 17210682 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Basal cell lymphoma | 17053054 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Cancer | 16751803 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Chronic lymphocytic leukemia | 17971485 | CNVD |
Basal cell lymphoma | 17170743 | CNVD |
Breast cancer | 16461572 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Follicular lymphoma | 17170743 | CNVD |
Human rectal carcinomas | 16397240 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Breast cancer | 17133270 | CNVD |
Chronic lymphocytic leukemia | 18922857 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Moyamoya disease | 22323933 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute promyelocytic leukemia | 19109227 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Myelodysplastic syndrome | 21251322 | CNVD |
Cancer | 20164919 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Acute myeloid leukemia | 20724749 | CNVD |
Non-syndromic sensorineural hearing loss | 21030649 | CNVD |
Acute myeloid leukemia | 17237825 | CNVD |
Colorectal cancer | 21645411 | CNVD |
HIV/AIDS | 22844521 | CNVD |
Psoriasis | 22844521 | CNVD |
Rheumatoid arthritis | 22844521 | CNVD |
Sclerosis systemic | 22844521 | CNVD |
Systemic lupus erythematosus | 22844521 | CNVD |
HIV/AIDS | 17953491 | CNVD |
HIV/AIDS | 20877625 | CNVD |
Immune disease | 21076436 | CNVD |
Rheumatoid arthritis | 17953491 | CNVD |
Type 1 diabetes | 17953491 | CNVD |
HIV/AIDS | 15637236 | CNVD |
Prostate cancer | 18632612 | CNVD |
Lung cancer | 18438408 | CNVD |
Ovarian cancer | 21781307 | CNVD |
Autism | 22495311 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Neurofibromatosis | 18196300 | CNVD |
Colorectal cancer | 16774939 | CNVD |
Breast cancer | 17001317 | CNVD |
Rhabdomyosarcoma | 16790082 | CNVD |
Charcot-marie-tooth disease | 16463004 | CNVD |
Osteosarcoma | 22292074 | CNVD |
Breast cancer | 17603634 | CNVD |
Charcot | 16760730 | CNVD |
Mental retardation | 17901693 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
ovarian endometriomas | 16273235 | CNVD |
Smith-Magenis syndrome | 18923513 | CNVD |
Invasive pancreatic ductal carcinoma | 16982739 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Breast cancer | 16272173 | CNVD |
Austim spectrum disorder | 21302340 | CNVD |
Autism | 22492990 | CNVD |
Congenital abnormalities | 21549014 | CNVD |
Developmental delay | 18414209 | CNVD |
Developmental delay | 21549014 | CNVD |
Epilepsy | 20970697 | CNVD |
Mental retardation | 18414209 | CNVD |
Mental retardation | 21549014 | CNVD |
Smith-Magenis syndrome | 21981782 | CNVD |
Smith-Magenis syndrome | 20188345 | CNVD |
Smith-Magenis syndrome | 16775514 | CNVD |
Smith-Magenis syndrome | 22585170 | CNVD |
Smith-Magenis syndrome | 22241247 | CNVD |
Autism | 20970697 | CNVD |
Mental retardation | 19951919 | CNVD |
Potocki-Lupski syndrome | 21271655 | CNVD |
Potocki-lupski syndrome | 17357070 | CNVD |
Potocki-lupski syndrome | 20110824 | CNVD |
Potocki-lupski syndrome | 18923514 | CNVD |
Potocki-lupski syndrome | 22241247 | CNVD |
Potocki-lupski syndrome | 20188345 | CNVD |
Schizophrenia | 21399695 | CNVD |
Mental retardation | 16773131 | CNVD |
Adenocarcinoma | 19607727 | CNVD |
Squamous cell cancer | 19607727 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Glioblastoma multiforme | 17002787 | CNVD |
Charcot-marie-tooth disease | 22470819 | CNVD |
Neurofibromatosis | 22470819 | CNVD |
Neuropathy | 22470819 | CNVD |
Smith-Magenis syndrome | 18301319 | CNVD |
Smith-Magenis syndrome | 17357070 | CNVD |
Smith-Magenis syndrome | 18469339 | CNVD |
Smith-Magenis syndrome | 22241097 | CNVD |
Smith-Magenis syndrome | 22470819 | CNVD |
Tourette syndrome | 18923514 | CNVD |
Type 1 diabetes | 22470819 | CNVD |
Potocki-lupski syndrome | 18469339 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
T-cell lymphomas | 19863542 | CNVD |
Neuropathy | 17597781 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Neurodevelopmental disorder | 17015230 | CNVD |
Smith-Magenis syndrome | 17597781 | CNVD |
Potocki-lupski syndrome | 18059269 | CNVD |
Potocki-lupski syndrome | 17597781 | CNVD |
Mental retardation | 17847001 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Breast cancer | 20409316 | CNVD |
Autism | 22543975 | CNVD |
Sezary syndrome | 18413736 | CNVD |
Cancer | 20164920 | CNVD |
Bipolar disorder | 19114987 | CNVD |
Breast cancer | 22522925 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr17:19499800-19519000 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
2 | chr17:19509000-19515600 | Weak transcription | A549 | lung |
3 | chr17:19513400-19515800 | Enhancers | Primary monocytes fromperipheralblood | blood |
4 | chr17:19515000-19515800 | Enhancers | GM12878-XiMat | blood |
5 | chr17:19515000-19518200 | Enhancers | Fetal Adrenal Gland | Adrenal Gland |
6 | chr17:19515600-19515800 | Enhancers | A549 | lung |
7 | chr17:19515800-19516800 | Weak transcription | A549 | lung |
8 | chr17:19516400-19517800 | Enhancers | Rectal Smooth Muscle | rectum |
9 | chr17:19516800-19517200 | Enhancers | Primary T helper cells fromperipheralblood | blood |
10 | chr17:19516800-19517200 | Enhancers | A549 | lung |
11 | chr17:19517000-19517400 | Enhancers | Duodenum Smooth Muscle | Duodenum |
12 | chr17:19517000-19517600 | Enhancers | Foreskin Melanocyte Primary Cells skin01 | Skin |
13 | chr17:19517000-19517600 | Enhancers | Foreskin Melanocyte Primary Cells skin03 | Skin |
14 | chr17:19517200-19517800 | Bivalent Enhancer | IMR90 fetal lung fibroblasts Cell Line | lung |
15 | chr17:19517200-19517800 | Enhancers | Ovary | ovary |
16 | chr17:19517200-19520800 | Weak transcription | Liver | Liver |
17 | chr17:19517400-19517600 | Enhancers | H1 Derived Mesenchymal Stem Cells | ES cell derived |
18 | chr17:19517400-19517600 | Enhancers | Stomach Smooth Muscle | stomach |
19 | chr17:19517400-19517800 | Enhancers | Colon Smooth Muscle | Colon |
20 | chr17:19518800-19519200 | ZNF genes & repeats | H1 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
21 | chr17:19519000-19519200 | ZNF genes & repeats | iPS DF 19.11 Cell Line | embryonic stem cell |
22 | chr17:19519000-19519200 | Bivalent Enhancer | Primary mononuclear cells fromperipheralblood | Blood |
23 | chr17:19520800-19521600 | ZNF genes & repeats | Primary neutrophils fromperipheralblood | blood |
24 | chr17:19520800-19523600 | ZNF genes & repeats | Liver | Liver |
25 | chr17:19521200-19523600 | ZNF genes & repeats | Mesenchymal Stem Cell Derived Adipocyte Cultured Cells | ES cell derived |
26 | chr17:19521400-19524400 | ZNF genes & repeats | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
27 | chr17:19521600-19523400 | ZNF genes & repeats | Adipose Nuclei | Adipose |
28 | chr17:19522000-19523200 | ZNF genes & repeats | Monocytes-CD14+_RO01746 | blood |
29 | chr17:19522400-19523200 | ZNF genes & repeats | A549 | lung |
30 | chr17:19525400-19538800 | Weak transcription | Ovary | ovary |